Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition

Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.